Evidence map›Paper›PMID 41486504›Full record

ArticleHuman vaccines & immunotherapeutics2025

Electronic, self-reported active vaccine safety surveillance: A three-country comparison of AusVaxSafety (Australia), CANVAS (Canada) and V-safe (United States).

Nicola Carter, Phyumar Soe, Lucy Deng, Jackson Young, Catherine King, Helen Quinn, Kristine Macartney, Julie A Bettinger, Nicholas Wood

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nicola CarterNational Centre for Immunisation Research and Surveillance, The Childrens Hospital at Westmead, Westmead, NSW, Australia.
Phyumar SoeVaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
Lucy DengNational Centre for Immunisation Research and Surveillance, The Childrens Hospital at Westmead, Westmead, NSW, Australia.
Jackson YoungNational Centre for Immunisation Research and Surveillance, The Childrens Hospital at Westmead, Westmead, NSW, Australia.
Catherine KingNational Centre for Immunisation Research and Surveillance, The Childrens Hospital at Westmead, Westmead, NSW, Australia.
Helen QuinnNational Centre for Immunisation Research and Surveillance, The Childrens Hospital at Westmead, Westmead, NSW, Australia.
Kristine MacartneyNational Centre for Immunisation Research and Surveillance, The Childrens Hospital at Westmead, Westmead, NSW, Australia.
Julie A BettingerVaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
Nicholas WoodNational Centre for Immunisation Research and Surveillance, The Childrens Hospital at Westmead, Westmead, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Active vaccine safety surveillance, which involves directly engaging with vaccine recipients to actively solicit information on adverse events following immunization, complements spontaneous reporting systems. This commentary provides a comparative overview of three national active vaccine safety surveillance systems: AusVaxSafety (Australia), CANVAS (Canada) and V-safe (United States) across six key surveillance system evaluation attributes. Each system played an essential role during the COVID-19 pandemic and continues to contribute to global post-marketing vaccine safety surveillance. Each has various strengths and limitations. AusVaxSafety, established in 2014, is well integrated with routine healthcare settings for opt-out surveillance and offers frequent public reporting. CANVAS, established in 2009, offers a unique cohort-based design with inclusion of control groups. V-safe, established in 2020, has proven scalability and broad population reach due to its accessible web-based design. The various features of each system offer insights to inform future vaccine safety surveillance efforts.

Indexed as

Adverse Drug Reaction Reporting SystemsCOVID-19COVID-19 VaccinesProduct Surveillance, PostmarketingVaccinesCanadaHumansSelf ReportUnited StatesVaccinationCOVID-19 VaccinesVaccinesActive vaccine safety surveillanceAustraliaAusVaxSafetyCanadaCANVASimmunisationpost-marketing surveillancesafetyUnited Statesvaccine safety surveillance systemsV-safe

Identifiers

PMID41486504
PMCPMC12773611

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.